Drug Search Results
More Filters [+]

Atorvastatin

Alternative Names: atorvastatin, lipitor, sortis, atorvastatina, tulip, lipilou, lipinon, artovastatin, atorvastatine, liptruzet, lypqozet
Latest Update: 2024-10-12
Latest Update Note: Clinical Trial Update

Product Description

Atorvastatin is used together with diet, weight loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. Atorvastatin is also used to decrease the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol ('bad cholesterol') and triglycerides in the blood and to increase the amount of high-density lipoprotein (HDL) cholesterol ('good cholesterol') in the blood.

Mechanisms of Action: HMG-CoA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atorvastatin

Countries in Clinic: Australia, Belgium, Canada, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Netherlands, Nigeria, Norway, Poland, Portugal, Russia, Spain, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 29

Highest Development Phases

Phase 3: Acute Pain|Breast Cancer|Dyslipidemia|Hypercholesterolemia|Hypertension|IgA Nephropathy|Obesity|Other|Prostate Cancer|Tuberculosis, Pulmonary

Phase 2: Hepatitis A|Hepatitis B|Hypertension, Portal|Inflammation|Kidney Cancer|Liver Cirrhosis|Ovarian Cancer|Triple Negative Breast Cancer

Phase 1: Conduct Disorder|Healthy Volunteers|Hyperlipidemia|Overweight|Pregnancy Outcomes|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2024-515404-39-00

P3

Unknown Status

Breast Cancer

2045-01-01

417-201-00012

P3

Unknown Status

IgA Nephropathy

2029-02-28

2016-004774-17

P3

Active, not recruiting

Prostate Cancer

2028-08-16

ESTO2

P3

Recruiting

Prostate Cancer

2025-12-31

Recent News Events